When does the pantoprazole patent expire?
The exact “patent expiry” date depends on which protection you mean—there are often multiple patents (drug substance, formulations, methods of use) and multiple jurisdictions (for example, the US versus Europe). A search for “pantoprazole patent expiry” typically also turns up different exclusivity concepts, not just a single end date.
If you tell me the country (US, UK, EU, etc.) and whether you mean the first generic launch or the last patent protection on a specific brand/product (for example, a particular marketed strength or formulation), I can narrow it to the relevant patent(s) and the corresponding expiry window.
What’s the difference between patent expiry and generic entry for pantoprazole?
Even after a patent expires, generic launch timing can still be affected by:
- Remaining patents (including secondary patents on formulations or dosing regimens)
- Regulatory exclusivities (which are separate from patent terms in many systems)
- Settlement agreements or regulatory litigation, if any exist for the relevant product
So “patent expiry” alone may not equal the earliest generic availability date.
How can I check pantoprazole patent expiry for a specific country or product?
For a reliable answer, you generally need:
- The specific market (country/region)
- The brand name or marketing authorization holder for that market
- The active ingredient strength and formulation (for example, enteric-coated vs. extended-release, if applicable)
- The patent family and listing in that jurisdiction’s patent/register system
If you share the brand/product name and country, I can guide you to the right patent lists and help interpret the expiry timeline.
Does pantoprazole have multiple patents, and do some expire later than others?
Yes. Many originator drug portfolios include more than one patent covering different aspects of the product (active ingredient, solid-state/formulation, manufacturing process, or specific uses). In practice, the “last expiry” across the relevant patent family is what often matters for generic timing.
Can exclusivity extend beyond patent expiry for pantoprazole?
In some regulatory regimes, exclusivity periods can continue even after certain patents expire, and they can delay approval or launch of generics/biosimilars depending on the product and local rules. The exact effect depends on the jurisdiction and the specific regulatory pathway used for the generic.
What information do I need from you to give the exact expiry date?
Reply with:
1) Country/region (US, EU/UK, etc.)
2) Brand or marketing authorization holder name (if you know it)
3) Strength/formulation (if relevant)
4) Are you asking about the originator brand, or a specific generic’s “first filing/launch” timing?
Then I can produce a precise expiry window tied to the correct pantoprazole patents/exclusivity items for that market.